ANAB - AnaptyBio Inc

-

$undefined

N/A

(N/A)

AnaptyBio Inc NASDAQ:ANAB Imsidolimab, previously known as ANB019, is an antibody that inhibits the function of the interleukin-36-receptor, or IL-36R, which AnaptysBio plans to initially develop as a potential first-in-class therapy for patients suffering from generalized pustular psoriasis, or GPP, EGFR-mediated skin toxicity, ichthyosis, hidradenitis suppurativa and acne.

Location: 10421 Pacific Center Ct Ste 200, California, 92121-4339, US | Website: www.anaptysbio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

450.6M

Cash

430.1M

Avg Qtr Burn

-25.75M

Short % of Float

36.77%

Insider Ownership

1.74%

Institutional Own.

-

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
JEMPERLI (Dostarlimb-gxly) Details
Solid tumor/s, Cancer, Endometrial cancer

Approved

Quarterly sales

Dostarlimab+ belrestotug Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Phase 3

Data readout

Dostarlimab Details
Non-small cell lung carcinoma, Cancer

Phase 3

Data readout

Imsidolimab (ANB019) (anti-IL-36R) Details
Hidradenitis suppurativa, Generalized pustular psoriasis, EGFRi-mediated skin toxicity, Ichthyosis, Palmoplantar pustulosis, Acne

Phase 3

Update

Rosnilimab (ANB030) (PD-1 agonist) Details
Rheumatoid arthritis, Autoimmune disease

Big Mover™

Phase 2b

Data readout

Phase 2

Data readout

Phase 1b

Update

Phase 1

Initiation

Etokimab (ANB020) Anti-IL-33 Details
Chronic Rhinosinusitis with Nasal Polyps

Failed

Discontinued

Failed

Discontinued

Rosnilimab (ANB030) (PD-1 agonist) Details
Alopecia areata, Vitiligo, Skin disease/disorder

Failed

Discontinued